Peptic Ulcer Drugs Market - Global Forecast 2026-2032

The Peptic Ulcer Drugs Market size was estimated at USD 4.99 billion in 2025 and expected to reach USD 5.26 billion in 2026, at a CAGR of 6.39% to reach USD 7.70 billion by 2032.

Peptic ulcer drugs encompass therapies used to reduce gastric acid, protect the gastrointestinal lining, eradicate Helicobacter pylori, and manage ulcer-related complications. Clinical practice increasingly emphasizes accurate diagnosis, cause-specific treatment, medication adherence, and prevention of recurrence rather than prolonged empirical acid suppression alone. Treatment selection varies according to infection status, bleeding risk, prior medication exposure, comorbidities, and local resistance patterns.

The treatment landscape is being reshaped by broader recognition of H. pylori as a preventable cause of ulcer disease, increased attention to nonsteroidal anti-inflammatory drug exposure, and stronger focus on preventing upper-gastrointestinal bleeding. Diagnostic confirmation, susceptibility-informed eradication where available, and post-treatment testing are becoming more important as antibiotic resistance complicates conventional regimens. Clinicians are also balancing symptom control with the need to use acid-suppressive medicines at the lowest effective intensity and duration, particularly in patients with multiple comorbidities or polypharmacy.

Artificial intelligence can contribute across the care pathway by identifying patients at risk of ulcer complications, supporting endoscopic image interpretation, extracting medication and symptom patterns from clinical records, and helping clinicians reconcile complex treatment histories. It may also assist with antimicrobial-resistance surveillance, adherence reminders, and prioritization of patients needing follow-up testing. However, reliable implementation requires representative clinical data, transparent validation, protection of patient information, and human oversight; AI should support, not replace, clinical judgment and guideline-based prescribing.

North America is characterized by established diagnostic and specialty-care infrastructure, with attention to appropriate acid-suppressant use, bleeding prevention, and resistant H. pylori infection. Europe combines mature healthcare systems with differing national guidelines, reimbursement arrangements, and antibiotic-resistance profiles. Asia-Pacific carries a substantial burden of H. pylori-associated disease and presents wide variation in diagnostic access, endoscopy capacity, and treatment availability. Latin America faces uneven access and important antimicrobial-resistance challenges, while prevention and primary-care integration remain central. In the Middle East, care pathways differ across health systems, with opportunities to strengthen testing, specialist referral, and continuity of treatment. Africa requires expanded access to diagnostics, essential medicines, endoscopy, and follow-up, alongside locally relevant resistance surveillance.

ASEAN markets reflect major differences in public-health capacity, private-care utilization, diagnostic access, and antibiotic stewardship, making adaptable treatment pathways important. BRICS members face varied burdens of H. pylori, healthcare infrastructure, and resistance surveillance, with domestic access and affordability shaping care. The European Union benefits from coordinated scientific and regulatory frameworks but retains national variation in reimbursement and clinical implementation. G7 systems generally have strong diagnostic capabilities and safety-monitoring processes, while managing aging populations and polypharmacy. GCC countries often combine advanced urban facilities with diverse patient populations and imported treatment practices. NATO members span highly different healthcare environments, so alliance membership does not imply uniform ulcer-drug access or prescribing standards.

Australia and Canada can build on strong primary and specialist care by reinforcing antimicrobial stewardship and follow-up testing. Brazil, Mexico, India, and South Africa need strategies that address unequal access, diagnostic delays, and resistance surveillance. China, Japan, and South Korea have substantial clinical capacity but must manage population aging, prescribing variation, and changing resistance patterns. France, Germany, Italy, Spain, and the United Kingdom have established guideline-based systems, with ongoing priorities including appropriate acid suppression, medication review, and equitable access across regions. Russia faces the need for consistent diagnostics, treatment continuity, and resistance-informed prescribing. In the United States, care pathways emphasize risk stratification, bleeding prevention, and management of persistent or resistant infection.

Industry leaders should prioritize regimens supported by current clinical evidence, clear dosing instructions, and practical adherence tools. They should invest in resistance surveillance, diagnostic partnerships, and evidence generation for difficult-to-treat or recurrent infection while avoiding unnecessary antibiotic exposure. Patient-support programs can reinforce completion of therapy, follow-up testing, and recognition of bleeding warning signs. Development and access strategies should account for local formularies, public-sector procurement, supply reliability, and health-literacy needs. Responsible AI initiatives should begin with narrowly defined use cases, prospective validation, cybersecurity controls, and clinician accountability.

This executive summary uses a structured review of established clinical principles for peptic ulcer management, including acid suppression, mucosal protection, H. pylori eradication, nonsteroidal anti-inflammatory drug risk reduction, and complication prevention. Interpretation is organized across the specified regions, country groupings, and countries, with attention to healthcare access, diagnostic capacity, antimicrobial resistance, regulation, and prescribing context. No market estimates, market shares, forecasts, or company-specific claims are included. Conclusions should be updated against current treatment guidelines, regulatory decisions, local resistance data, and peer-reviewed clinical evidence.

The peptic ulcer drugs landscape is moving toward individualized, cause-directed management supported by accurate diagnosis, responsible antimicrobial use, and prevention of recurrence and bleeding. Regional and national differences in access, resistance, and healthcare capacity make standardized principles necessary but local implementation essential. Leaders who connect therapeutic development with diagnostics, adherence support, safety monitoring, and validated digital tools will be best positioned to improve the quality and continuity of ulcer care.